Caroline Baumal - 16 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Medical Officer
Signature: /s/ David Watson, attorney-in-fact for Caroline Baumal
Issuer symbol: APLS
Transactions as of: 16 Jan 2024
Net transactions value: +$2,453,100
Form type: 4
Filing time: 17 Jan 2024, 16:33:45 UTC
Previous filing: 05 Jan 2024
Next filing: 08 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+25,445	+77%	$0.000000	58,376	16 Jan 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$2,453,100	+37,000		$66.30	37,000	16 Jan 2024	Common Stock	37,000	$66.30	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
F2	This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.